|
|
 |
DOMPERIDONE
PEPRIDONTM
10 mg Tablet
GASTROKINETIC
FORMULATION:
Each uncoated tablet contains:
Domperidone ………….............................. 10 mg |
PHARMACOKINETICS :
The systematic bioavailability of domperidone is only about 15% in fasting subjects given a dose by mouth,
although this is increased when domperidone is given after food. The low availability is thought to be due to
first-pass hepatic and intestinal metabolism. The bioavailability of rectal domperidone is similar to that following
oral administration, although peak plasma concentrations are only achieved after about an hour, compared with
30 minutes after a dose by mouth. It is more than 90% bound to plasma protein, and has a terminal
elimination half-life of about 7.5 hours. It is chiefly cleared from the blood by extensive metabolism. About
30% of an oral dose is excreted in urine within 24 hours, almost entirely as metabolites; the remainder of a
dose is excreted in faeces over several days, about 10% as unchaged drug. It does not readily cross the bloodbrain
barrier. Small amounts of domperidone are distributed into breast mild, reaching concentrations about
one quarter of those in maternal serum.
INDICATIONS :
Used as an antiemetic for the short-term treatment of nausea and vomiting of various aetiologies, including that
associated with cancer therapy, and nausea and vomiting associated with levodopa or bromocriptine therapy for
parkinsonism. Also used for its prokinetic actions in dyspepsia and has been tried in diabetic gastroparesis.
DRUG INTERACTIONS:
Similarly to other dopamine antagonists, there is a theoretical potential that domperidone may antagonize the
hypoprolactinaemic effect of drugs such as bromocriptine. In addition, the prokinetic effects of domperidone
may alter the absorption of some drugs. Oploid analgesics and antimuscarinics may antagonize the prokinetic
effects of domperidone.
ADVERSE EFFECTS :
Plasma-prolactin concentrations may be increased which may lead to galactorrhoea or gynaecomastia. There
have been reports of reduced libido, and rashes and other allergic reactions. It does not readily cross the
blood-brain barrier and the incidence of central effects such as extrapyramidal reactions or drowsiness may be
lower than with metoclopramide; however, there have been reports of dystonic reactions.
PRECAUTIONS :
It is not recommended for chronic administration or for the routine prophylaxis of postoperative nausea and
vomiting. Domperidone should be used with great caution if given intravenously, because the risk of
arrhythmias, especially in patients predisposed to cardiac arrhythmias or hypokalaemia.
DOSAGE AND ADMINISTRATION :
For acute treatment of nausea and vomiting : 10 mg to 20 mg by mouth every 4 to 8 hours.
For the symptomatic treatment of non-ulcer dyspepsia : adults may receive up to 10 mg to 20 mg by mouth
3 times daily before meals and at night, depending on clinical response. A course of treatment should not
exceed 12 weeks.
In migraine : a dose of 20 mg by mouth may be taken up to every 4 hours, in combination with paracetamol,
as required, up to a maximum of 4 doses in 24 hours. Or as prescribed by the physician.
WARNING:
This product contains tartrazine which cause allergic reactions to some sensitive individual.
AVAILABILITY:
Domperidone 10 mg Tablet Pack in blister foil (10 x 10 Tablets) Box of 100’s
CAUTION:
Foods, Drugs, Devices, and Cosmetics Act prohibits dispensing without prescription.
STORE AT TEMPERATURES NOT EXCEEDING 30° C.
Pepridon is a trademark of XENO Pharmaceuticals Phils. Inc.
|
|
|
